H Fujii has received honoraria for lectures from Ono Pharm, Chugai Pharm, and Taiho Pharm. M Tsuchiya has received honoraria for lectures from Ono Pharm, Chugai Pharm, Taiho Pharm, Sun Pharm and Kyowa Kirin. D Watanabe has received honoraria for lectures from Chugai Pharm. D Hirate has received honoraria for lectures from Taiho Pharm, Daiichi Sankyo, Eli Lilly and Company, Pfizer Eisai, Takeda Pharm, Bristol Myers Squibb, EA Pharma, MSD Japan, Kyowa Kirin, Chugai Pharm, Yakult Honsha, Nippon Kayaku, Eisai, Meiji Seika Pharma, Merck Bio Pharma, AstraZeneca plc and Sun Pharma. Y Ando has received honoraria for lectures from Yakult Honsha, Taiho Pharm, Daiichi Sankyo, Pfizer Eisai. N Matsunami has received honoraria for lectures from Pfizer Eisai, Daiichi Sankyo and Eli Lilly and Company. N Matsuhashi has received both honoraria for lectures and grants made to institution from Taiho Pharm. J Nishimura has received honoraria for lectures from Taiho Pharm. N Inui has received honoraria for lectures from Taiho Pharm, AstraZeneca plc and Chugai Pharm. A Suzuki has received honoraria for lectures from Toa Eiyo, Asahi Kasei Pharma, Daiichi Sankyo, Pfizer Eisai, Nippon Shinyaku, Celltrion Healthcare Japan, Otsuka Pharm, Sandoz, Tsumura, Nipro, Taiho Pharm, Kyowa Kirin, Nippon Chemiphar, Japan Blood Products Organization, Takeda Pharm, and Nippon Boehringer Ingelheim and grants made to institution from Nippon Kayaku, Asahi Kasei Pharma, Chugai Pharm, Taiho Pharm, Daiichi Sankyo, Japan Blood Products Organization, Mochida Pharm, Sun Pharma and consulting fees from Nippon Kayaku. H Iihara has received honoraria for lectures from Taiho Pharm, Chugai Pharma, Yakult Honsha, Astellas Pharma, Eli Lilly and Company, Daiichi Sankyo, AstraZeneca plc, Nippon Kayaku, Ono Pharm, and Nippon Boehringer Ingelheim; and consulting fees from Pfizer Eisai and Taiho Pharm. The other authors have no conflicts of interest.